Cargando…

Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma

BACKGROUND: The fibroblast growth factor receptor 4 (FGFR4) pathway is an essential regulatory component of bile acid synthesis, and its relationship with hepatocellular carcinoma (HCC) has been reported. We investigated the gene expression and clinical significance of FGFR4 and related pathways in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Kang, Jihoon, Kim, Deokhoon, Kim, Kyu-Pyo, Ryoo, Baek-Yeol, Hong, Seung-Mo, Hwang, Jung Jin, Jeong, Seong-Yun, Hwang, Shin, Kim, Ki-Hun, Lee, Young-Joo, Hoeflich, Klaus P., Schmidt-Kittler, Oleg, Miller, Stephen, Choi, Eun Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503556/
https://www.ncbi.nlm.nih.gov/pubmed/28445152
http://dx.doi.org/10.18632/oncotarget.16951
_version_ 1783249122564767744
author Yoo, Changhoon
Kang, Jihoon
Kim, Deokhoon
Kim, Kyu-Pyo
Ryoo, Baek-Yeol
Hong, Seung-Mo
Hwang, Jung Jin
Jeong, Seong-Yun
Hwang, Shin
Kim, Ki-Hun
Lee, Young-Joo
Hoeflich, Klaus P.
Schmidt-Kittler, Oleg
Miller, Stephen
Choi, Eun Kyung
author_facet Yoo, Changhoon
Kang, Jihoon
Kim, Deokhoon
Kim, Kyu-Pyo
Ryoo, Baek-Yeol
Hong, Seung-Mo
Hwang, Jung Jin
Jeong, Seong-Yun
Hwang, Shin
Kim, Ki-Hun
Lee, Young-Joo
Hoeflich, Klaus P.
Schmidt-Kittler, Oleg
Miller, Stephen
Choi, Eun Kyung
author_sort Yoo, Changhoon
collection PubMed
description BACKGROUND: The fibroblast growth factor receptor 4 (FGFR4) pathway is an essential regulatory component of bile acid synthesis, and its relationship with hepatocellular carcinoma (HCC) has been reported. We investigated the gene expression and clinical significance of FGFR4 and related pathways in intrahepatic cholangiocarcinoma (iCCA). RESULTS: The median age was 56 years (range 30–78) and 34 patients (74%) were male. Six patients (13%) had hepatitis B virus infection, with or without liver cirrhosis. Overall survival was significantly associated with FGFR4 (p = 0.004), FGF19 (p = 0.047), FGF21 (p = 0.04), and KLB (p = 0.03) expression. In the multivariate analysis with potential prognostic factors, high expression of FGF19, FGF21, and FGFR4 was significantly associated with better survival. In the analysis using the TCGA iCCA dataset, mRNA overexpression of at least 1 of the FGFR4-related genes was significantly associated with better disease-free survival (p = 0.02). MATERIALS AND METHODS: We assessed the expression of 98 genes in formalin-fixed paraffin embedded tumor tissue specimens from 46 patients with surgically resected iCCA using a NanoString platform. This included 10 FGF pathway genes (e.g. FGFR1-4, KLB, FGF3, 4, 19, 21, and 23), 19 distal marker genes (e.g. CYP7A1 and CYP17A1), 31 genes relevant to HCC and iCCA (e.g. AFP, TS), 18 copy number variation matched genes, and 20 control genes. Log-transformation of gene expression was performed for normalization and statistical analysis. Overall survival was correlated with gene expression (< median vs. ≥ median) using a log-rank test. The prognostic impact of FGFR4-related genes was validated using the public TCGA dataset for iCCA. CONCLUSIONS: Our results indicate that mRNA expression of FGFR4-related genes may be a biomarker to define the distinctive molecular phenotype of iCCA. Future preclinical and clinical validation is required to define the role of the FGFR4 pathway in iCCA.
format Online
Article
Text
id pubmed-5503556
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55035562017-07-11 Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma Yoo, Changhoon Kang, Jihoon Kim, Deokhoon Kim, Kyu-Pyo Ryoo, Baek-Yeol Hong, Seung-Mo Hwang, Jung Jin Jeong, Seong-Yun Hwang, Shin Kim, Ki-Hun Lee, Young-Joo Hoeflich, Klaus P. Schmidt-Kittler, Oleg Miller, Stephen Choi, Eun Kyung Oncotarget Research Paper BACKGROUND: The fibroblast growth factor receptor 4 (FGFR4) pathway is an essential regulatory component of bile acid synthesis, and its relationship with hepatocellular carcinoma (HCC) has been reported. We investigated the gene expression and clinical significance of FGFR4 and related pathways in intrahepatic cholangiocarcinoma (iCCA). RESULTS: The median age was 56 years (range 30–78) and 34 patients (74%) were male. Six patients (13%) had hepatitis B virus infection, with or without liver cirrhosis. Overall survival was significantly associated with FGFR4 (p = 0.004), FGF19 (p = 0.047), FGF21 (p = 0.04), and KLB (p = 0.03) expression. In the multivariate analysis with potential prognostic factors, high expression of FGF19, FGF21, and FGFR4 was significantly associated with better survival. In the analysis using the TCGA iCCA dataset, mRNA overexpression of at least 1 of the FGFR4-related genes was significantly associated with better disease-free survival (p = 0.02). MATERIALS AND METHODS: We assessed the expression of 98 genes in formalin-fixed paraffin embedded tumor tissue specimens from 46 patients with surgically resected iCCA using a NanoString platform. This included 10 FGF pathway genes (e.g. FGFR1-4, KLB, FGF3, 4, 19, 21, and 23), 19 distal marker genes (e.g. CYP7A1 and CYP17A1), 31 genes relevant to HCC and iCCA (e.g. AFP, TS), 18 copy number variation matched genes, and 20 control genes. Log-transformation of gene expression was performed for normalization and statistical analysis. Overall survival was correlated with gene expression (< median vs. ≥ median) using a log-rank test. The prognostic impact of FGFR4-related genes was validated using the public TCGA dataset for iCCA. CONCLUSIONS: Our results indicate that mRNA expression of FGFR4-related genes may be a biomarker to define the distinctive molecular phenotype of iCCA. Future preclinical and clinical validation is required to define the role of the FGFR4 pathway in iCCA. Impact Journals LLC 2017-04-07 /pmc/articles/PMC5503556/ /pubmed/28445152 http://dx.doi.org/10.18632/oncotarget.16951 Text en Copyright: © 2017 Yoo et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Yoo, Changhoon
Kang, Jihoon
Kim, Deokhoon
Kim, Kyu-Pyo
Ryoo, Baek-Yeol
Hong, Seung-Mo
Hwang, Jung Jin
Jeong, Seong-Yun
Hwang, Shin
Kim, Ki-Hun
Lee, Young-Joo
Hoeflich, Klaus P.
Schmidt-Kittler, Oleg
Miller, Stephen
Choi, Eun Kyung
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
title Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
title_full Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
title_fullStr Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
title_full_unstemmed Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
title_short Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
title_sort multiplexed gene expression profiling identifies the fgfr4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503556/
https://www.ncbi.nlm.nih.gov/pubmed/28445152
http://dx.doi.org/10.18632/oncotarget.16951
work_keys_str_mv AT yoochanghoon multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT kangjihoon multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT kimdeokhoon multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT kimkyupyo multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT ryoobaekyeol multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT hongseungmo multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT hwangjungjin multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT jeongseongyun multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT hwangshin multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT kimkihun multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT leeyoungjoo multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT hoeflichklausp multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT schmidtkittleroleg multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT millerstephen multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma
AT choieunkyung multiplexedgeneexpressionprofilingidentifiesthefgfr4pathwayasanovelbiomarkerinintrahepaticcholangiocarcinoma